Middle East & Africa Human Albumin Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The Middle East & Africa Human Albumin Market size is expected to reach US$ 211.7 Million by 2031 from US$ 163.1 Million in 2024. The market is estimated to record a CAGR of 3.9% from 2025 to 2031.

Executive Summary and Middle East & Africa Human Albumin Market Analysis:

According to the World Health Organization (WHO) 2022 data, the Eastern Mediterranean Region bears the highest global burden of chronic Hepatitis C virus (HCV) infection, with an estimated 12 million people chronically infected. This high HCV prevalence leads to a significant rate of liver diseases, such as cirrhosis and hepatocellular carcinoma, which are primary indications for human albumin infusion to manage ascites and hypovolemia. The region is experiencing a critical epidemiological shift, with Non-Alcoholic Fatty Liver Disease (NAFLD) emerging as a major contributor to liver pathology in line with global trends observed by the Global Burden of Disease (GBD) 2021 study. Beyond therapeutics, there is a rising demand for albumin in non-therapeutic applications, particularly as a stabilizer in vaccine and drug formulation, and as a component in advanced cell culture media for the developing biopharmaceutical sector across the MEA. This trend is driven by recent technological advancements in recombinant albumin production.

Middle East & Africa Human Albumin Market: Strategic Insights

Middle East & Africa Human Albumin Market Segmentation Analysis:

• By Application, the Middle East & Africa Human Albumin Market is segmented into Therapeutic Applications, Drug Delivery, Disease Diagnostics, Research, and Others. The Therapeutic Applications segment dominated the market in 2024.
• By Therapeutic Application, the Middle East & Africa Human Albumin Market is segmented into Liver and Kidney Diseases, Surgery, Hypovolemia and Hypoalbuminemia, and Others. The Hypovolemia and Hypoalbuminemia segment dominated the market in 2024.
• By End User, the Middle East & Africa Human Albumin Market is segmented into Hospitals and Clinics, Pharmaceutical and Biotechnological Companies, Research Institutes, Diagnostic Laboratories, Homecare Settings, and Others. The Hospitals and Clinics segment dominated the market in 2024.

Middle East & Africa Human Albumin Market Players Density: Understanding Its Impact on Business Dynamics

The Middle East & Africa Human Albumin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Middle East & Africa Human Albumin Market Outlook

There is a gradual shift in source and formulation of albumin therapies moving from traditional plasma-derived human albumin toward recombinant albumin and other engineered products. While direct clinical market share, data are limited in official sources, industry analyses indicate that recombinant albumin is gaining traction because it offers advantages in supply chain, pathogen risk reduction, and consistency. The trend toward recombinant albumin reflects an underlying market movement suppliers and hospitals are preparing for a future where albumin is not just used as a volume expander but as a more engineered molecule. The shift may open up new regulatory pathways and product labels (for instance, albumin as part of drug formulations or targeted therapies) rather than only plasma-derived generic albumin solutions.

Middle East & Africa Human Albumin Market Country Insights

By country, the Middle East & Africa Human Albumin Market is segmented into Saudi Arabia, South Africa, the United Arab Emirates, and the Rest of Middle East & Africa. Saudi Arabia held the largest share in 2024.

According to the Saudi Center for Organ Transplantation (SCOT) 2024 report, liver transplants hit a record 422, supported by 1,706 donors-up 4.9% from 1,626 in 2023. Total organs transplanted reached 2,091 in 2023, a 30% increase. According to the Ministry of Health (MOH) Statistical Yearbook 2023, 1,049,113 surgical operations occurred, including 641,870 in MOH hospitals and 2,046 intensive care procedures. Burn cases via the Saudi Red Crescent totaled 3,060. Hepatitis B cases surged to 7,658, with an incidence of 22.7 per 100,000. ICU bed occupancy hit 65.4% amid 1.4 million inpatients. These trends drive albumin for volume expansion and hypoalbuminemia. According to the Saudi Food and Drug Authority (SFDA), labeling updates for Flexbumin (Nov 2024) and Human Albumin 20% (Sep 2024) ensure supply reliability.

Middle East & Africa Human Albumin Market Company Profiles

Some of the key players operating in the market include CSL Ltd, Biotest AG., Octapharma AG, Takeda Pharmaceutical Co Ltd, Merck KGaA, Grifols SA, Taibang Bio Group Co. Ltd., HiMedia Laboratories Pvt Ltd, Thermo Fisher Scientific Inc., and InVitria.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Middle East & Africa Human Albumin Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise